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Abstract
Background: MR-guided focused ultrasound (MRgFUS) might be a very safe and effective minimally invasive
technique to treat facet joint pain caused by arthritis and other degenerative changes. However, there are still
safety concerns for this treatment and challenges regarding MR imaging and temperature mapping due to
susceptibility effects between the bone and soft tissue near the joint, which has resulted in poor MR image
quality. The goal of this research was to evaluate multiple magnetic resonance imaging (MRI) pulse sequences for
characterizing ablated lumbar facet joint lesions created by high-intensity focused ultrasound (FUS) and compare
the findings to histological tissue assessment. In particular, we investigated the use of T2-weighted MRI to assess
treatment effects without contrast administration.
Methods: An IACUC approved study (n = 6 pigs) was performed using a 3T widebore MRI system equipped
with an MRgFUS system. Facet joints of the lumbar vertebra were ablated using 1-MHz frequency and multiple
sonication energies (300–800 J). In addition to T2-weighted MRI for treatment planning, T1-, T2-, and T2*-weighted
and perfusion MRI sequences were applied. Signal intensity ratios of the lesions were determined. Histopathology
was used to characterize cellular changes.
Results: Ablation of the facet joint, using MRgFUS, was successful in all animals. T2-weighted images showed high
signal intensity in the edematous facet joint and adjacent muscle, while delayed contrast-enhanced T1-weighted
images showed an enhanced ring surrounding the target volume. T2*-weighted GRE images revealed inconsistent
lesion visualization. Histopathology confirmed the presence of cellular coagulation (shrinkage), extracellular
expansion (edema), and hemorrhage in the bone marrow.
Conclusions: MRgFUS provided sufficient precision and image quality for visualization and characterization of
ablated facet joints directly after ablation. MRI may help in monitoring the efficacy of FUS ablation without contrast
after treating patients with back pain.
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Background
Interest in MR-guided focused ultrasound (MRgFUS) has
increased tremendously over the past few years. In
MRgFUS, focused ultrasound beams are combined with
real-time magnetic resonance imaging (MRI) monitoring
to perform controlled thermal ablation [1]. This combined
modality is well suited for targeting, characterizing, and
quantifying pathologic tissues [2–4]. MRgFUS has recently
emerged as an effective treatment option for ablating uter-
ine fibroids [5–10], bone metastases [11], breast cancer
[12], hepatocellular carcinoma [13], brain cancer [14], and
treating brain cancer by opening the blood-brain barrier
[15]. Recently, MRgFUS has also been applied to the treat-
ment of facet joints in patients with lower back pain and
bone metastasis [16, 17]. Significant improvement in pa-
tient lifestyle was evident after treatment [17].
In MRgFUS, image guidance is extremely important
for both treatment planning and real-time temperature
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monitoring. MRI can provide instant information on
temperature changes in tissues [18] that plays an import-
ant role in treatment planning and tissue necrosis. It also
ensures safety monitoring of the procedure and energy
deposition. Although much attention has been paid to
the optimization of thermometry approaches for
MRgFUS [19, 20], less focus has been placed on the
optimization of MR protocols for characterization of ab-
lated tissues after treatment. In particular, imaging tech-
niques for lesion detection without the need of contrast
would allow potential repetitions of focused ultrasound
(FUS) treatment within the same session. However, this
is not possible once contrast has been administered [21].
Hijnen et al. [22] investigated several effects of contrast
agent before FUS treatment. They found a significant
frequency shift due to local magnetic field from the
contrast agent, which resulted in wrong calculations for
temperature and dose. Furthermore, short-term trap-
ping of contrast in the coagulated tissue volume was
observed, but no effect on long-term retention was
found. Thus, lesion visualization without the need of
contrast would be an important progress for clinical ap-
plications of MRgFUS. Harnof et al. recently showed
that visualization and characterization of facet joint le-
sions after thermal ablation is particularly challenging
with very limited MR image quality [16]. Thus, the goal
of this study was to further optimize and evaluate mul-
tiple MRI sequences for characterizing ablated lumbar
facet joint created by FUS.
Methods
Animal preparation
All experimental procedures received approval from the
Institutional Animal Care and Use Committee (IACUC).
Six healthy female farm pigs (Pork Power Farms, Turlock,
CA) were premedicated with 0.5 mg/kg acepromazine
(PromAce; Fort Dodge Animal Health, Fort Dodge, IA)
and 30 min later 25 mg/kg ketamine (Ketaset; Fort
Dodge Animal Health). The pigs were then anesthe-
tized with a mixture of isoflurane 2–5 % and oxygen.
Saline (10 mL/kg/h) was intravenously infused throughout
the experiment for hydration. Vital signs (heart rate, elec-
trocardiogram (ECG), respiratory rate, O2-saturation)
were monitored throughout the procedure. To minimize
muscle twitching and diaphragm motion during inspir-
ation and expiration in anesthetized pigs, rocuronium
(0.1 mg/kg) was intravenously administered prior to
ablation.
MRgFUS setup and treatment
All FUS experiments were performed using the ExAblate
2000 System (InSightec Ltd., Tirat Carmel, Israel) with a
phased array transducer of 208 elements embedded in
the MR scanner table. The table was connected to a 3T
MRI widebore scanner (see details below). The skin
around the targeted treatment areas was shaved for each
animal, cleaned, and closely examined for any skin defects
or scars, which might impede the propagation of acoustic
energy from the transducer. Each pig was then placed
onto a gel pad on the scanner table in a supine position,
inside a shallow bath filled with degassed water.
A three-plane localizer was performed to verify ad-
equate positioning relative to the transducer. T2-weighted
treatment planning sequences were added. Adequate
coverage of all treated facet joints was obtained with 3-
mm slice thickness. The planning images were then trans-
ferred to the ExAblate workstation where the target bone
was segmented (Fig. 1) and the skin surface was identified.
Low-energy test sonications were performed in the mus-
cles far away from the target in order to calibrate the FUS
beam location. Three to four lumbar facet joints (L3/4-
L6/7) on the left side of the animal were ablated per pig
Fig. 1 T2-weighted planning images are shown with the focal spot on the facet joint (left image). The beam orientation was chosen to best
protect the spinal nerve roots, the spinal canal, and the spinal process as outlined in green. After HIFU treatment, the area of ablation is shown in
blue (dose overlay) on the right image
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using an ultrasound frequency of 1 MHz and the fol-
lowing spot energies: 300 J (duration = 25 s, acoustic
power = 15 W, cooling duration = 25 s), 500 J (duration =
25 s, acoustic power = 20 W, cooling duration = 25 s),
650 J (duration = 25 s, acoustic power = 25 W, cooling
duration = 25 s), and 800 J (duration = 25 s, acoustic
power = 32 W, cooling duration = 25 s). The energies were
selected in order to cover the range used in previous pub-
lication for facet joint ablation [16, 17].
We have treated one side of three to four vertebral
levels, thus three to four facet joints per animal. We
have identified a central MRI slice from the planning im-
ages of each facet joint and added one more slice on
each side for the whole treatment volume. We have ap-
plied two partially overlapping sonication on each slice
resulting in a total of six sonications per joint. The
temperature was assessed during each sonication using
echo planar imaging (EPI) as previously described [20, 23].
The temperature rise was measured at the focal point and
in the far field adjacent to the intervertebral foramen.
MR imaging
All imaging was performed on a 3T widebore scanner
(Discovery MR 750w, GE Healthcare, Waukesha, WI).
For signal acquisition, the default body coil was used
and a 64 channel receive only cardiac coil (GE Health-
care, Waukesha, WI). In addition to T2-weighted MRI
for the treatment planning, several MR images were ac-
quired before and immediately after FUS treatment (see
Table 1 for imaging parameters). The pulse sequences
included axial, sagittal, and coronal 2D T1-weighted fast
spin echo (T1-FSE), a 2D T2-weighted FSE with fat sat-
uration (T2-FSE), and 2D T2*-weighted gradient recalled
echo (T2*-GRE). First-pass perfusion was performed
using axial 2D gradient echo with FOV = 28 cm, slice
thickness = 5 mm, and a matrix size of 96 × 96 voxels.
T2*-GRE and T2-FSE were performed before and after
FUS application but before contrast injection. T1-FSE
was performed before and after FUS application as well
as after contrast injection. Bolus injection of 2 mmol/kg
gadolinium diethylenetriamine pentaacetate (Gd-DTPA)
was delivered after the FUS treatment for perfusion and
delayed contrast enhancement (DCE) imaging after
treatment.
Image and statistical analysis
On all acquired images, the patterns of delineation of
the treated facet joints were compared to the untreated
contralateral joints. Signal to noise (SNR) was evaluated
as the mean signal intensity (SI) in the region of interest
divided by the standard deviation of the noise, while SI
ratio (SIR) was determined by dividing SI of ablated le-
sion over surrounding normal tissues. Thus, SIR <1 was
defined as hypointense, SIR = 1 as isointense, and SIR >1
as hyperintense. Contrast to noise ratio (CNR) was eval-
uated by the difference in signal between two regions di-
vided by the standard deviation of the noise. Images
were assessed for the presence of edema on the T2-FSE
images as well as loss of cellular and vascular integrity
on DCE T1-FSE and T2*-GRE images. SI(s) as a func-
tion of time were also measured in ablated and sur-
rounding normal tissues on perfusion images. Paired
Student’s t test was used for statistical analysis. Data
were presented as mean ± SEM and a P value less than
0.05 was considered significant.
Histology
Animals were heparinized prior to euthanasia. All ani-
mals were sacrificed ~4 h after ablation by IV injection
of saturated potassium chloride. Formalin (4 %) was in-
fused for 1 h to fix the tissue in situ. Tissue samples
(treated and contralateral non-treated facet joints and
paravertebral muscles) were obtained, sliced, and fixed
in 70 % formalin. Microscopic sections (5 μm) were
stained with hematoxylin and eosin stain (H&E) and ex-
amined microscopically. Histopathological sections
through the paravertebral muscles, dorsal root ganglion,
and facet joint were acquired.
Results
The instant temperature changes were monitored during
treatment using the standard proton resonance fre-
quency (PRF) method with echo planar MRI [20]. The
mean temperature during sonication was 62.7 ± 9.8 °C.
After the procedure, the capability of each pulse se-
quence to depict the ablated facet joints and adjacent
tissue was determined. Table 1 shows the differences in
scan time and spatial resolution between the used pulse
sequences. Our study showed that the image quality
Table 1 MR sequences and imaging parameter
Pulse sequence TR (ms) TE (ms) ETL rBW (kHz) Flip angle (°) Slice (mm) In-plane resolution (mm) Scan time
T1-FSE 600–800 6.5 6 31.25 90 3–5 1–1.5 3’13”
T2-FSE 4500–8300 68 12 15.63 90 3–5 1–1.5 4’01”
T2*-GRE 1550 15 N.A. 19.23 30 4 1–1.5 5’04”
Perfusion 3.7 1.5 N.A. 62.5 9 5–7 2.9 4’57”
The scan times varied according to coverage and number of slices for the different orientations
N.A. not applicable
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from the body coil was sufficient to clearly visualize the
lesions. We found a gain in SNR of a factor of 1.7 by
switching the body coil to a 64 channel cardiac coil, but
this required changing the table and position of the ani-
mal and may lead to misregistration of the images.
T1-FSE failed to provide sufficient contrast between
ablated and adjacent normal tissues prior to administra-
tion of contrast media (Fig. 2). Gd-DTPA delineated the
ablated region by enhancing the signal at the border
zone (hyperemia), suggesting that the diffusion of con-
trast media was limited due to vascular damage. After
contrast administration, all lesions were depicted with
negative contrast to the surrounding tissue on T1-FSE
(Figs. 2, 3, and 4) and demonstrated focal ovoid hypoen-
hancement (SIR = 0.8) of the bone and soft tissue at the
target volume with a thin rim of hyperenhancement
(SIR = 1.6). These findings confirmed the presence of ne-
crosis and vascular damage that led to the exclusion of
Gd-DTPA from entering to the core of the lesion.
On T2-FSE (Figs. 3, 4, and 5), the lesions were clearly
shown as hyperintense (SIR = 3.9) after ablation but be-
fore contrast injection, suggesting the presence of inter-
stitial edema. Although SNR was in general higher on
post-contrast DCE T1-FSE, CNR between the lesions
and the normal tissue was factor 1.8 higher on T2-FSE.
For comparisons, additional sonications were per-
formed in the skeletal muscle adjacent to the facet joint
and paravertebral muscles. Again, the interstitial edema
can be appreciated on T2-FSE where the lesions are
shown as hyperintense (Fig. 6) compared to surrounding
tissue in all lesions (SIR = 1.90 and SIR = 2.50). DCE T1-
FSE showed again focal hypoenhancement and sur-
rounding hyperemia.
T2*-GRE images acquired after sonication showed
small, inconsistent hyperintense (SIR = 1.5) zones close
to the treated area. This was not observed at the
contralateral joints (Fig. 7). These hyperintense zones
appeared smaller than the edematous regions on T2-
FSE images.
A lack of differential contrast between the ablated
facet joint or paravertebral muscles and normal adjacent
tissues was found on first-pass perfusion images, which
can be attributed to a trade-off between time resolution,
spatial resolution, number of covered slices, and slice
thickness.
Microscopic examination confirmed the locations of
the ablated tissue, which include coagulation necrosis
(shrinkage of the cells) and expansion of extracellular
space (interstitial edema) (Fig. 8). No evidence of dam-
age was found in the dorsal root ganglion or the spinal
cord as a result of thermal ablation (Fig. 9). Evidence of
hemorrhage was seen in the treated facet joint (Fig. 10).
Fig. 2 Coronal T1-FSE images. a Baseline. b After FUS ablation. c After both FUS and contrast injection. The lesions were delineated, as
hypoenhanced zone, after administration of 0.15 mmol/kg Gd-DTPA, suggesting lack of delivery of the contrast media due to the damage
of microvessels
Fig. 3 Coronal T2-FSE (left) and DCE T1-FSE (right) after FUS treatment.
The T2-FSE image shows a positive contrast of the lesions. The DCE T1-
FSE image shows the hyperenhancement of the border zone, but not
the core of ablated lesion. The following energies were applied (from
top to bottom): 650, 300, 500, and 800 J, and the arrows indicate
ablated lesions. A positive relationship between energy and lesion size
can be appreciated in both images
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But there was no change in the architecture of the
osteoblast, most likely due to the short period of exam
after ablation.
Discussion
Using MRgFUS, the ideal imaging protocol should have
the following two characteristics. First, it should be
highly sensitive to acute tissue changes to allow for ac-
curate evaluation of the treatment. Second, it should
allow repetitions of the treatment if necessary. The later
demand would exclude the use of contrast agents. The
goal of this work was to present a comprehensive study
for MRgFUS treatment of the facet joint investigating
several MR pulse sequences, sonication energies, and
histological findings. Compared to a previous study by
Harnof et al. [16], we have further enhanced MR im-
aging using T1-FSE with and without contrast, T2-FSE,
T2*-GRE, and perfusion sequences and confirmed out-
comes by histology. One of the major findings of our
study is that T2-FSE MRI can provide excellent post-
FUS lesion detection without the need of contrast
administration. This has important implications for the
FUS procedure because the ablation can be immediately
evaluated and retreated if necessary. This is not possible
once contrast has been administered.
Both pre-contrast T2-FSE and post-contrast DCE T1-
FSE sequences have the potential to delineate ablated
facets and surrounding tissues. Microscopic examination
of biopsies confirmed the thermal effects on tissues adja-
cent to the facet joints and lumbar vertebrae. T2-FSE
showed strong positive contrast with hyperintense lesion
signal suggesting the presence of edema in the lesion. In
addition, slightly increased blood flow (hyperemia) could
also be observed in the peripheral zones similar to DCE
(Figs. 3, 4, and 5). Although the scan time was slightly
increased on T2-FSE scans (Table 1), there was no
need for administration of contrast media or delay
time (typically 10 min) for imaging. Thus, this might
be a fast approach for lesion detection and verification
immediately after treatment. We found that a 3-mm
slice thickness and 192 matrixes provided the best
trade-off between image quality, contrast, and scan
time for all sequences (Table 1). Previously, inconsist-
ent results have been reported using T2-weighted im-
ages, e.g., heterogeneous appearance was shown after
FUS in uterine fibroids [24], prostate [25], and pancre-
atic tumors [26].
In addition to T2-FSE and DCE, T2*-GRE might be
useful to distinguish edema from hemorrhage in ablated
lesions. T2*-GRE images inconsistently showed small
Fig. 4 Axial T2-FSE (left) and DCE T1-FSE (right) after FUS treatment. The T2-FSE image shows a positive contrast of the lesions. The DCE T1-FSE
image shows the hyperenhancement of the border zone, but not the core of ablated lesion
Fig. 5 Axial T2-weighted images. a Acquired before FUS. b After FUS treatment. The lesion is clearly visible as hyperintense signal,
suggesting the presence of edema. The sonication energy used for the depicted joint was 800 J. Smaller lesion sizes were generated with
smaller sonication energies
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hyperintense lesions that were visible adjacent to the
treated joint. It has previously been shown that T2*-GRE
is limited in detecting interstitial edema [27]. Due to a
trade-off between time resolution, spatial resolution,
coverage, and slice thickness, we were unable to obtain
meaningful perfusion results. Despite the above limita-
tions, this study provides a basis for further development
and standardization of the different techniques. A previ-
ous study indicated that the mechanism of loss of vascu-
lar integrity during MRgFUS ablation is unclear [28].
Hynynen et al. [1] indicated that noninvasive vascular
occlusion could be achieved using thermal MRgFUS,
and Wu et al. [29] suggested that the cause of perfusion
deficits after FUS ablation is vascular damage. Our histo-
logical study indicated that the skeletal muscle showed
coagulation necrosis and damaged microvessels after
FUS treatment. The damaged vessels with coagulated
blood most likely played a critical role in preventing
blood perfusion and delivery of MR contrast media to
the core of the ablated lesion.
This study showed further that thermal ablation
causes shrinkage of the cells and expansion of extracel-
lular space. The expansion of extracellular space is un-
related to extravasation of albumin from the vascular
compartment, because extracellular Gd-DTPA was un-
able to diffuse to the core of the lesions. A dynamic re-
lationship exists between the extracellular and
intracellular water. Water molecules exchange passively
between intravascular, interstitial, and intracellular com-
partments under normal circumstances. Water volume in
each compartment is determined by mechanisms control-
ling intracellular osmotic pressure, including ion homeo-
stasis and metabolism, and water transport through
sarcolemmal channels and membrane diffusion. Regula-
tion of intracellular pH is an important element in os-
motic regulation. ATP-dependent Na+/K+ pump and
intracellular proteins maintain the balance between intra-
and extracellular water [30]. All these elements can be in-
fluenced by energy metabolism. It has been shown that
brief myocardial ischemia leads to energy deficiency, so-
dium overload, cell swelling, and water dissociation from
proteins because of lactate-induced acidosis, thereby in-
creasing the intracellular fraction of free unbound water
[31, 32]. We have also looked at treatment effects on bone.
Although there was evidence of hemorrhage in the treated
facet joint, no change in the architecture of the osteoblast
was found. As these effects need more time to manifest, a
longitudinal study is clearly warranted.
Fig. 6 Sagittal MR images of the paraventricular muscles obtained on T2-FSE (left) and DCE T1-FSE. T2-FSE image shows the hyperintense
edematous ablated lesion, while T1-FSE image shows the donut pattern enhancement after administration of Gd-DTPA
Fig. 7 Representative axial T2*-weighted images acquired before (a) and after (b) FUS ablation. The slice location corresponds to the slices
depicted in Fig. 4. A small hyperintense lesion is visible after ablation (arrow)
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During FUS treatment, there should be no RF coil in
the field of the sonication. Thus, the default body coil
needs to be used for treatment planning but could po-
tentially be replaced after treatment. However, we found
that the default body coil of the MR system provided
sufficient image quality to characterize regional tissue
changes (edema, viability) after treatment. Although
switching from the default body coil to a phased array
coil after FUS treatment provided better SNR, it did not
improve lesion detection but was time-consuming and
compromised image registration.
The rise in temperature was used to define the target
and may not reflect the actual temperature in the target.
Furthermore, PRF-based MRI temperature mapping is
very sensitive to off-resonance effects near tissue inter-
faces such as between the bone and muscle and may
thus be inconsistent and not reliable near the facet joint.
Thus, calibration is usually done within the muscle tis-
sue, and this might be a problem in patients with severe
facet arthritis where it might be very difficult to find a
homogenous muscle layer. However, since lethal cell
damage occurs when temperatures >55 °C are maintained
for longer than a second [33], accurate temperature
measurements are crucial to monitor the treatment
and to evaluate treatment outcomes. Furthermore, post-
sonication MRI could potentially be a helpful marker to
identify necrotic areas where these high temperatures were
met (see Fig. 8). These needs to be further investigated.
The ultimate goal of using MRgFUS for facet joint
ablation is to produce lasting pain relief to the patient.
Recently, Weeks et al. demonstrated the in vivo applic-
ability of MRgFUS for facet joint palliation with rela-
tively small energies (average 600 J) [17]. They reported
no improvements in pain scores in 40 % of the patients
most likely due to the low energies used. Very recently,
another group from Europe presented preliminary re-
sults from a clinical study with 35 patients where they
used sonication energies of up to 2300 J [34]. They re-
ported no adverse events and 28 patients had a signifi-
cant reduction in pain. These results suggest that there
is a trade-off between safety and efficacy of MRgFUS
and higher sonication energies might be more efficient.
However, safety becomes increasingly a concern with
higher energies, and clearly, more animal studies are
warranted to investigate the optimal treatment strategy
while ensuring patient safety.
Fig. 8 Sagittal image and histopathological section through the paravertebral muscles show the wedge shape-ablated lesion on DCE (left) and
microscopy (right). Arrows denote the necrotic core with damaged tissue. Note the border edematous hyperenhanced zone (arrowheads)
surrounding the ablated core on DCE (scale shows the SI range in arbitrary units). The border edematous zone is also seen on microscopy
(arrowheads, calibration bar = 100 μm)
Fig. 9 Microscopic sections of dorsal root ganglion after 800-J sonication showing no evidence of injury in neural cells or axons. Magnifications
are ×10, ×40, and ×100
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Conclusions
In conclusion, we have evaluated several MRI pulse se-
quences for the assessment of FUS treatment and veri-
fied the findings with histology. We found that T2-FSE
provides good image quality with positive contrast be-
tween the ablated lesion and surrounding tissues and
could reduce the imaging cost and overall treatment
time, as no contrast agent is needed and thus continuous
FUS treatment would be possible. T1-FSE, with the aid
of MR contrast media, delineated the borders of ablated
lesions and provided evidence of vascular obstruction.
Demonstration of perfusion deficit on first-pass perfu-
sion imaging is challenging in the facet joints and needs
further improvement. Microscopy revealed the cellular
and vascular changes after ablation and provided direct
evidence on the causes of hyperintensity on T2-FSE and
hyperenhancement on DCE T1-FSE images. In sum-
mary, we have presented acute findings in the facet joint
after FUS ablation. However, many changes on the tissue
level need more time to manifest. Thus, the next import-
ant step of this research would be a longitudinal study
to investigate changes over time.
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